THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC
Status:
Completed
Trial end date:
2016-03-26
Target enrollment:
Participant gender:
Summary
This will be an open-label, parallel group, multiple dose study in approximately 48 healthy
male or female subjects of African American and Caucasian self-reported race, to assess the
effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and
CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians
in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).